Video

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

Author(s):

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago

Transcript:

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Richard T. Lee, MD, Cherng Family Director’s Chair, Center for Integrative Oncology, medical director, clinical professor, Supportive & Integrative Medicine, Department of Supportive Care Medicine, City of Hope
Rachna T. Shroff, MD, MS
Daneng Li, MD, associate professor, Department of Medical Oncology & Therapeutics Research, and co-director, Neuroendocrine Tumor Program, City of Hope
Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer
Susumu Hijioka, MD, PhD
Kanwal PS Raghav, MBBS, MD
Vikas S. Ostwal, MD
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Related Content
2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

SAR444200 in Solid Tumors | Image Credit: © Katsyarina – stock.adobe.com
March 11th 2025

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Gastric/GEJ Adenocarcinoma | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 7th 2025

Perioperative Durvalumab Plus Chemo Meets EFS End Point in Resectable Gastric/GEJ Cancer

HCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 7th 2025

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC